ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management

American Journal of Transplantation

Volumn 16, Issue 3, 2016, Pages 886-896

  Okumi, M ^a   Toki, D ^a   Nozaki, T ^a   Shimizu, T ^a   Shirakawa, H ^a   Omoto, K ^a   Inui, M ^a   Ishida, H ^a   Tanabe, K ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; BLOOD GROUP ABO SYSTEM; IMMUNOSUPPRESSIVE AGENT;

ABO INCOMPATIBLE LIVING KIDNEY TRANSPLANTATION; ADENOVIRUS INFECTION; ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SURVIVAL RATE; UNRELATED DONORS; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION; GLOMERULUS FILTRATION RATE; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; LIVING DONOR; MIDDLE AGED; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84959473318     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13502     Document Type: Article

References (35)

1. Takahashi K, Saito K, Takahara S, et al., Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089-1096.
2. Takahashi K, Saito K., Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplantation 2006; 13: 118-122.
3. Tanabe K, Takahashi K, Sonda K, et al., Long-term results of ABO-incompatible living kidney transplantation: A single-center experience. Transplantation 1998; 65: 224-228.
4. Opelz G, Morath C, Susal C, Tran TH, Zeier M, Dohler B., Three-year outcomes following 1,420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: Results from 101 centers. Transplantation 2015; 99: 400-404.
5. Takahashi K, Saito K., ABO-incompatible kidney transplantation. Transplant Rev (Orlando) 2013; 27: 1-8.
6. Tanabe K, Tokumoto T, Ishida H, et al., ABO-incompatible renal transplantation at Tokyo Women's Medical University. Clin Transpl 2003; 175-181.
7. Tanabe K, Tokumoto T, Ishida H, et al., Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc 2004; 36: 2175-2177.
8. Tanabe K., Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84 (Suppl): S4-S7.
9. Ishida H, Miyamoto N, Shirakawa H, et al., Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation-Single center analysis. Am J Transplant 2007; 7: 825-831.
10. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T., Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61-74.
11. Ishida H, Tanabe K, Furusawa M, et al., Mycophenolate mofetil suppresses the production of anti-blood-type antibodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity. Transplantation 2002; 74: 1187-1189.
12. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K., Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22: 447-454.
13. Shirakawa H, Ishida H, Shimizu T, et al., The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: A single-center experience. Clin Transplant 2011; 25: 878-884.
14. Shimmura H, Tanabe K, Ishida H, et al., Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005; 80: 985-988.
15. Hirai T, Kohei N, Omoto K, Ishida H, Tanabe K., Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012; 25: 925-934.
16. Onitsuka S, Yamaguchi Y, Tanabe K, Takahashi K, Toma H., Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplant 1999; 13 (Suppl 1): 33-37.
17. Tyden G, Kumlien G, Fehrman I., Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730-731.
18. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I., ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148.
19. Gloor JM, Cosio FG, Rea DJ, et al., Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847.
20. Sonnenday CJ, Warren DS, Cooper M, et al., Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322.
21. Gloor JM, Stegall MD., ABO incompatible kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16: 529-534.
22. Fehr T, Gaspert A., Antibody-mediated kidney allograft rejection: Therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623-632.
23. Tyden G, Ekberg H, Tufveson G, Mjornstedt L., A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: A 3-year follow-up. Transplantation 2012; 94: e21-e22.
24. Ashimine S, Watarai Y, Yamamoto T, et al., Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int 2014; 85: 425-430.
25. van den Hoogen MW, Kamburova EG, Baas MC, et al., Rituximab as induction therapy after renal transplantation: A randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 2015; 15: 407-416.
26. Tanabe K, Ishida H, Inui M, et al., ABO-incompatible kidney transplantation: Long-term outcomes. Clin Transpl 2013; 307-312.
27. Segev DL, Simpkins CE, Warren DS, et al., ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5: 2570-2575.
28. Tyden G, Donauer J, Wadstrom J, et al., Implementation of a protocol for ABO-incompatible kidney transplantation-A three-center experience with 60 consecutive transplantations. Transplantation 2007; 83: 1153-1155.
29. Montgomery RA, Locke JE, King KE, et al., ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009; 87: 1246-1255.
30. Genberg H, Kumlien G, Wennberg L, Tyden G., Isoagglutinin adsorption in ABO-incompatible transplantation. Transfus Apher Sci 2010; 43: 231-235.
31. Nishida H, Ishida H, Tanaka T, et al., Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy. Transpl Int 2009; 22: 961-969.
32. Lentine KL, Axelrod D, Klein C, et al., Early clinical complications after ABO-incompatible live-donor kidney transplantation: A national study of Medicare-insured recipients. Transplantation 2014; 98: 54-65.
33. Kahwaji J, Sinha A, Toyoda M, et al., Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894-2900.
34. Kamar N, Milioto O, Puissant-Lubrano B, et al., Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89-98.
35. Habicht A, Broker V, Blume C, et al., Increase of infectious complications in ABO-incompatible kidney transplant recipients-A single centre experience. Nephrol Dial Transplant 2011; 26: 4124-4131.